Sonnet Biotherapeutics HoldiSONN
13F holders, Q1 2025 (March 31)8holders −1
3new positions
4sold out
$1.34avg. 13F price*
At the end of Q1 2025, 8 institutions reported holding Sonnet Biotherapeutics Holdi (SONN) in their 13F filings, down 1 from Q4 2024. 3 opened new positions and 4 sold out. The largest holders were MMCAP International Inc. SPC ($179K), Geode Capital Management, LLC ($33K) and Tower Research Capital LLC (TRC) ($3K).
- Company
- Sonnet Biotherapeutics Holdi
- CUSIP
- 83548R402
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $212K |
| Exits | 4 | $121K |
All 13F filers, Q4 2024 → Q1 2025: 158,571 shares bought and 86,378 shares sold, net +72,193 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| MMCAP International Inc. SPC | 0.03% | New | 133,590 | $179K |
| Geode Capital Management, LLC | 0.00% | New | 24,805 | $33K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -57.6% | 2,587 | $3K |
| UBS Group AG | 0.00% | Add +4600.0% | 141 | $189 |
| BlackRock, Inc. | 0.00% | No change | 65 | $87 |
| Carolina Wealth Advisors, LLC | 0.00% | No change | 32 | $43 |
| Bank of America Corp. | 0.00% | Add +420.0% | 26 | $35 |
| Barclays PLC | 0.00% | New | 17 | $23 |
"% of holder's portfolio" is SONN's weight in each manager's 13F, not the share of Sonnet Biotherapeutics Holdi the manager owns.